Registry for Advanced Non-Small Cell Lung Cancer Treatment
Met Non Small Cell Cancer Registry (MOMENT)
Recruiting
Observational Study
Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 700 (estimated)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
Who this trial is looking for
This trial is looking for people with advanced non-small cell lung cancer who have certain genetic changes. Participants will share their treatment experiences and outcomes as part of a larger study.
Are You a Good Fit for This Trial?
You may be able to join if
- I have signed an informed consent form.
- I have been diagnosed with advanced stage non-small cell lung cancer.
- I have confirmed METex14 skipping alterations.
- I am starting or am already being treated with systemic therapy.
You may not be able to join if
- I am currently enrolled in another clinical trial.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment pattern…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants who signed ICF
* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
* Participants who are starting or are already being treated with systemic therapy
Exclusion Criteria:
* Partic…
Contacts